Geron Corporation
CompanyUnited StatesFounded 1990
Geron Corporation develops 2 assets, the furthest approved (Imetelstat in myelodysplastic syndrome). Mostly oligonucleotide acting on TERT; based in the United States, founded in 1990.
- 2
- Assets
- Furthest stage
- Approved
- 16
- Trials
- 6
- Signals
Pipeline
2Inhibits telomerase, depriving cancer cells of continued growth and survival.
Approved, Oligonucleotide, TERT, myelodysplastic syndrome, anemia
Telomerase inhibitor
Phase 3, Oligonucleotide, myelofibrosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials23
- Deals9
- People17
- Signals10
- Similar companies6
Papers
Leukemia, Jan 12, 2026
PloS one, Mar 14, 2013
Blood, Mar 27, 2003
Extension of life-span by introduction of telomerase into normal human cells
Science (New York, N.Y.), Jan 16, 1998
Nature genetics, Dec 1, 1997
Telomerase catalytic subunit homologs from fission yeast and human
Science (New York, N.Y.), Aug 15, 1997
Telomere length and replicative aging in human vascular tissues
Proceedings of the National Academy of Sciences of the United States of America, Nov 21, 1995